Policy Notices

• Reminders of NIH Policies Related to Closeout
  (NOT-OD-21-102)
  National Institutes of Health
  

General Notices

• Notice of NIGMS Funding Priorities for PAR-19-301 "Limited Competition: NIGMS National and Regional Resources (R24 Clinical Trial Not Allowed)"
  (NOT-GM-21-036)
  National Institute of General Medical Sciences
  

• Updated Notice of Information: NHLBI Extensions for Career Development Award (K01, K08, K23, K25) Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19
  (NOT-HL-21-009)
  National Heart, Lung, and Blood Institute
  

• Notice of Correction to Key Dates of NOT-MH-21-105, Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure
  (NOT-MH-21-255)
  National Institute of Mental Health
  

• Notice of Correction to NOT-OD-21-071 Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focuses on Maternal Health, Structural Racism and Discrimination, and COVID-19
  (NOT-OD-21-090)
  National Institutes of Health
  

• RESCINDED - Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic: January 2022 Council
  (NOT-OD-21-095)
  National Institutes of Health
  

• Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Optional)
  (NOT-OD-21-097)
  National Institutes of Health
  

• Registration is Now Open for the 2021 HHS Small Business Program Conference on April 26-30!
  (NOT-OD-21-098)
  National Institutes of Health
  

• The National Institutes of Health (NIH) Sexual & Gender Minority Research Office Request for Nominations for 2021 SGM Research Investigator Awards Program
  (NOT-OD-21-099)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice of Change: Extension of PA-18-926, Primary Caregiver Technical Assistance Supplements (PCTAS) (Admin Supp Clinical Trial Optional)
  (NOT-AI-21-042)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Expansion of Research Scope of RFA-AI-21-004 "Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)
  (NOT-AI-21-044)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in PAR-21-109 Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
  (NOT-AI-21-047)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Clarification of Eligibility Regarding Foreign Components for PAR-19-257, "Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03)"
  (NOT-AR-21-021)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Change to Key Dates for NIDA PAR-21-183, " Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)"
  (NOT-DA-21-042)
  National Institute on Drug Abuse
  

• Notice of Change to Key Dates for NIDA PAR-21-208, " Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)"
  (NOT-DA-21-043)
  National Institute on Drug Abuse
  

• Notice of Change to Funding Opportunities for NOT-EB-20-017, "Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications"
  (NOT-HD-21-017)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Change in Advisory Council Review for RFA-MD-21-006 "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)"
  (NOT-MD-21-017)
  National Institute on Minority Health and Health Disparities
  

• Notice of Participation of NIMH in NOT-EY-21-001, "Notice of Special Interest (NOSI): National Research Service Award (NRSA) F32 Postdoctoral Fellowship Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities"
  (NOT-MH-21-245)
  National Institute of Mental Health
  

• Notice of Extension to PAR-18-894, "Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)"
  (NOT-MH-21-250)
  National Institute of Mental Health
  

• Notice of Change to Expiration Date for OBSSR RFA-OD-21-005 "Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 - Independent Clinical Trial Not Allowed)
  (NOT-OD-21-096)
  Office of Behavioral and Social Sciences Research
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
  (NOT-CA-21-045)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)
  (NOT-CA-21-050)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Clinical Validation Centers
  (NOT-CA-21-051)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement: Early Detection Research Network (EDRN) Data Management and Coordinating Center
  (NOT-CA-21-052)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for New Investigators to Promote Workforce Diversity in Genomics and other Health-Related Research (R01 Clinical Trial Optional)
  (NOT-HG-21-024)
  National Human Genome Research Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Joint NINDS and NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
  (NOT-NS-21-050)
  National Institute of Neurological Disorders and Stroke
  National Institute of Mental Health
  

• Notice of Intent to Publish the Reissuance of RFA-NS-18-020, BRAIN Initiative: Novel Technologies and Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
  (NOT-NS-21-051)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  

• Notice of Intent to Publish the Reissuance of RFA-NS-18-019, BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)
  (NOT-NS-21-052)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  

• Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
  (NOT-NS-21-055)
  National Institute of Neurological Disorders and Stroke
  

Requests for Proposal

• 2021 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 Now Available
  (NOT-AI-21-045)
  National Institute of Allergy and Infectious Diseases
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain
  (NOT-DA-21-001)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Identification of Biomarkers of HIV Pathogenesis and Substance Use Disorder Comorbidity
  (NOT-DA-21-014)
  National Institute on Drug Abuse
  

• Notice of Special Interest: Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21)
  (NOT-HD-21-024)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children
  (NOT-MH-21-225)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Special Interest (NOSI) for Illuminating the Druggable Genome (IDG) Initiative: Request for Administrative Supplements to Existing Grants for incorporating single cell data into the IDG Knowledgebase
  (NOT-RM-21-019)
  Office of Strategic Coordination (Common Fund)
  

Funding Opportunities

• Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)
  (PA-21-199)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
  (PA-21-200)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)
  (PA-21-201)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Short-Term Mentored Research Career Enhancement Award to Promote Diversity (K18 No Independent Clinical Trials)
  (PA-21-214)
  National Human Genome Research Institute
  Application Receipt Date(s): June 12, 2021, February 12, 2022, February 12, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applications are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
  (PAR-21-162)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): August 10, 2021, February 9, 2022, August 9, 2022, February 9, 2023, August 9, 2023, February 9, 2024
  
  

• Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed)
  (PAR-21-185)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): May 28, 2021; September 24, 2021; January 27, 2022; May 27, 2022; September 21, 2022; January 27, 2023; May 26 2023; September 26, 2023. January 29, 2024.
  
  

• NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed)
  (PAR-21-187)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): May 28, 2021; September 24, 2021; January 27, 2022; May 27, 2022; September 21, 2022; January 27, 2023; May 26, 2023; September 26, 2023; January 29, 2024
  
  

• Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)
  (PAR-21-196)
  National Institute of General Medical Sciences
  Application Receipt Date(s): October 14, 2021; October 14, 2022; October 13, 2023
  
  

• NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (PAR-21-197)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)
  (PAR-21-210)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)
  (PAR-21-211)
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-009)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed)
  (RFA-AI-21-012)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed)
  (RFA-AI-21-019)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): August 24, 2021
  
  

• Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)
  (RFA-AI-21-023)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)
  (RFA-AI-21-024)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)
  (RFA-AI-21-025)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
  (RFA-AR-21-015)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Allergy and Infectious Diseases
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)
  (RFA-AR-21-016)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Allergy and Infectious Diseases
  National Institute of Dental and Craniofacial Research
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed)
  (RFA-DA-22-002)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Nutrition Obesity Research Centers (P30 Clinical Trial Optional)
  (RFA-DK-21-015)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)
  (RFA-HD-22-010)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 29, 2021
  
  

• User-Based Design to Aid in Contraceptive Development by Small Business (R43 Clinical Trial Not Allowed)
  (RFA-HD-22-019)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 29, 2021
  
  

• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial Not Allowed)
  (RFA-HG-21-006)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)
  (RFA-HG-21-007)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
  (RFA-HG-21-008)
  National Human Genome Research Institute
  Application Receipt Date(s): June 25, 2021; March 1, 2022; February 1, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
  (RFA-RM-21-012)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Intramural - Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2/UH3 Clinical Trial Not Allowed)
  (RFA-TR-21-015)
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Multiple dates, see announcement.